Artiva Biotherapeutics Inc (ARTV)
11.90
+0.71
(+6.34%)
USD |
NASDAQ |
Nov 05, 16:00
11.96
+0.06
(+0.50%)
After-Hours: 20:00
Artiva Biotherapeutics Enterprise Value: 135.15M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 135.15M |
| November 01, 2024 | 126.36M |
| October 31, 2024 | 116.16M |
| October 30, 2024 | 116.34M |
| October 29, 2024 | 128.82M |
| October 28, 2024 | 124.25M |
| October 25, 2024 | 121.79M |
| October 24, 2024 | 116.51M |
| October 23, 2024 | 130.40M |
| October 22, 2024 | 136.56M |
| October 21, 2024 | 122.14M |
| October 18, 2024 | 151.85M |
| October 17, 2024 | 162.58M |
| October 16, 2024 | 177.00M |
| October 15, 2024 | 158.89M |
| October 14, 2024 | 189.13M |
| October 11, 2024 | 203.37M |
| October 10, 2024 | 186.67M |
| October 09, 2024 | 198.45M |
| October 08, 2024 | 199.15M |
| October 07, 2024 | 193.00M |
| October 04, 2024 | 216.21M |
| October 03, 2024 | 208.65M |
| October 02, 2024 | 214.28M |
| October 01, 2024 | 209.00M |
| Date | Value |
|---|---|
| September 30, 2024 | 209.53M |
| September 27, 2024 | 184.21M |
| September 26, 2024 | 172.08M |
| September 25, 2024 | 203.55M |
| September 24, 2024 | 163.28M |
| September 23, 2024 | 158.54M |
| September 20, 2024 | 156.95M |
| September 19, 2024 | 144.12M |
| September 18, 2024 | 147.11M |
| September 17, 2024 | 130.40M |
| September 16, 2024 | 110.18M |
| September 13, 2024 | 113.00M |
| September 12, 2024 | 126.71M |
| September 11, 2024 | 140.43M |
| September 10, 2024 | 145.17M |
| September 09, 2024 | 148.87M |
| September 06, 2024 | 149.22M |
| September 05, 2024 | 147.28M |
| September 04, 2024 | 137.96M |
| September 03, 2024 | 131.46M |
| August 30, 2024 | 140.78M |
| August 29, 2024 | 136.56M |
| August 28, 2024 | 130.05M |
| August 27, 2024 | 125.66M |
| August 26, 2024 | 127.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
110.18M
Minimum
Sep 16 2024
216.21M
Maximum
Oct 04 2024
148.24M
Average
142.36M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 3.645M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 9.837M |
| Theriva Biologics Inc | -12.61M |
| Oragenics Inc | 1.996M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.96M |
| Revenue (Quarterly) | 0.251M |
| Total Expenses (Quarterly) | 14.74M |
| EPS Diluted (Quarterly) | -0.7941 |
| Profit Margin (Quarterly) | -5.56K% |
| Earnings Yield | -25.77% |
| Normalized Earnings Yield | -25.64 |